Rotavirus vaccine coverage, completion, and compliance: A systematic literature review.

IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-01-03 DOI:10.1080/21645515.2024.2442780
Halima Tahrat, Ali Munir, Federico Marchetti
{"title":"Rotavirus vaccine coverage, completion, and compliance: A systematic literature review.","authors":"Halima Tahrat, Ali Munir, Federico Marchetti","doi":"10.1080/21645515.2024.2442780","DOIUrl":null,"url":null,"abstract":"<p><p>Rotavirus, a leading cause of severe acute gastroenteritis in children, is largely preventable through immunization with two internationally licensed oral rotavirus vaccines (RVVs) included in national programs across over 100 countries. These RVVs are administered in either two (Rotarix™; 2D-RV) or three (RotaTeq®; 3D-RV) doses. We aimed to assess the global coverage, completion, and compliance of 2D-RV and 3D-RV in various settings, and to identify factors influencing vaccine coverage. We conducted a systematic review of PubMed and Embase for articles published between 2006 and 2021. We included 74 publications across 31 countries. RVV coverage rates and the factors associated with coverage varied widely among countries based on income level, RVV used, and the year of vaccination. Due to market bias and insufficient studies, valid RVVs coverage comparisons couldn't be made. However, 2D-RV had better completion/compliance rates than 3D-RV in Italy, Mexico, and the US.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2442780"},"PeriodicalIF":4.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2442780","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Rotavirus, a leading cause of severe acute gastroenteritis in children, is largely preventable through immunization with two internationally licensed oral rotavirus vaccines (RVVs) included in national programs across over 100 countries. These RVVs are administered in either two (Rotarix™; 2D-RV) or three (RotaTeq®; 3D-RV) doses. We aimed to assess the global coverage, completion, and compliance of 2D-RV and 3D-RV in various settings, and to identify factors influencing vaccine coverage. We conducted a systematic review of PubMed and Embase for articles published between 2006 and 2021. We included 74 publications across 31 countries. RVV coverage rates and the factors associated with coverage varied widely among countries based on income level, RVV used, and the year of vaccination. Due to market bias and insufficient studies, valid RVVs coverage comparisons couldn't be made. However, 2D-RV had better completion/compliance rates than 3D-RV in Italy, Mexico, and the US.

轮状病毒疫苗的覆盖、完成和依从性:系统的文献综述。
轮状病毒是导致儿童严重急性胃肠炎的主要原因,在很大程度上可通过免疫接种得到预防,100多个国家的国家规划包括两种国际许可的口服轮状病毒疫苗(RVVs)。这些rvv通过以下两种方式进行管理(Rotarix™;2D-RV)或三个(RotaTeq®;3 d-rv)剂量。我们的目的是评估2D-RV和3D-RV在不同情况下的全球覆盖率、完成度和依从性,并确定影响疫苗覆盖率的因素。我们对2006年至2021年间发表的PubMed和Embase文章进行了系统综述。我们纳入了31个国家的74份出版物。根据各国的收入水平、使用的裂谷病毒和接种年份,裂谷病毒覆盖率和与覆盖率相关的因素差别很大。由于市场偏见和研究不足,无法进行有效的RVVs覆盖率比较。然而,在意大利、墨西哥和美国,2D-RV的完成率/合规率高于3D-RV。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
CiteScore
7.90
自引率
8.30%
发文量
489
审稿时长
3-6 weeks
期刊介绍: (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信